

EVALUATION OF PCOS IN OBESE AND NON-OBESE INDIVIDUALS THROUGH ULTRASOUND

Zahra Sakhi*¹, Sadia Sabir²

¹Department of Radiological Sciences & Medical Imaging Technology Faculty of Allied Health Sciences Superior University Lahore, Email: zahrasakhi786@gmail.com

²Department of Human Nutrition and Food Technology Faculty of Allied Health Sciences Superior University Lahore, Email: sadia.sabir@superior.edu.pk

*Corresponding author: Zahra Sakhi, ¹Department of Radiological Sciences & Medical Imaging Technology Faculty of Allied Health Sciences Superior University Lahore, Email: zahrasakhi786@gmail.com

Abstract:

Introduction: Polycystic ovary syndrome (PCOS) is a common hormonal disorder affecting women of reproductive age. It is characterized by irregular periods, excess androgen levels, and polycystic ovaries, often leading to fertility issues and metabolic complications

Aim of Study: To compare the ultrasound features of polycystic ovaries between obese and non-obese patients.

Methodology: A prospective observational design was conducted at Gilani Ultrasound Center in Lahore. A total of 100 participants were included using a non-probability purposive sampling technique. Data collection spanned a period of 9 months. The study included females of all ages, categorized into four groups: obese with PCOS, obese without PCOS, non-obese with PCOS, and non-obese without PCOS. Exclusion criteria encompassed females with treated PCOS, those undergoing infertility treatment, individuals with congenital anomalies, and those with ovarian abnormalities other than

PCOS.

Results: This study on polycystic ovary syndrome (PCOS) included 126 participants with a mean age of 28.7 ± 4.6 years, of whom 66.7% were diagnosed with polycystic ovaries. The mean body mass index (BMI) was 27.6 ± 5.1 , with a significant association found between PCOS and obesity ($p = 0.01$). Mean ovarian volumes were similar for both ovaries (left: $16.452 \pm 8.2930 \text{ cm}^3$; right: $16.573 \pm 8.2358 \text{ cm}^3$), which are higher than previously reported values. Clinically, PCOS was significantly associated with a string-like appearance of the ovaries ($p < 0.001$), diabetes ($p = 0.040$), hypertension ($p = 0.040$), amenorrhea ($p < 0.001$), and infertility ($p = 0.02$). Hormonal analyses showed significant links with thyroid dysfunction, progesterone, luteinizing hormone (LH), testosterone, and follicle-stimulating hormone (FSH).

Conclusion: These findings underscore the complex nature of PCOS and its associations with metabolic and hormonal disturbances, highlighting the need for a comprehensive approach to diagnosis and management

Keywords: Body Mass Index (BMI), Polycystic ovarian syndrome (PCOS), Metabolic Syndrome (METs), Infertility, Primary infertility.

Introduction:

PCOS is a prevalent disease that affects 4%-8% of females of childbearing age according to estimated prevalence data from the National Institute of health¹⁻⁵. Several studies have discovered that the incidence of PCOS varies depending on the diagnostic criteria utilized. Based on studies, the prevalence assessed using the Rotterdam criteria is two to three times higher than the prevalence assessed using the NIH/NICHD criteria.⁶⁻⁹

However, the basic etiology of the polycystic ovarian syndrome is uncertain; important symptoms include insulin resistance, aberrant gonadotropin dynamics, and androgen excess. In comparison to insulin resistance, obesity affects roughly 65 to 70% of women with polycystic ovarian syndrome, and obesity is linked to insulin resistance. Insulin resistance is greater in women with polycystic ovary syndrome than in other women in the general population¹⁰. A past history of PCOS is another risk factor for the condition.

PCOS is thought to be a heritable illness based on many instances in families^{11,12}. The significant frequency of polycystic ovary syndrome among first-degree relatives suggests that genetic factors are involved^{13,14}. Polycystic ovaries syndrome affects 85% of women who report with signs of androgen excess¹⁵. Hirsutism is the most prevalent clinical manifestation of hyperandrogenism, affecting more than 70% of women with PCOS¹⁶. Acne is less prevalent in PCOS and not as frequent, as hirsutism but it can also be a marker of hyperandrogenism around 15%–30% of adult women with PCOS have clinical presentation of acne¹⁷. More than 40% of women presented with acne were diagnosed with PCOS¹⁸.

This study aimed to determine the relationship between specific ultrasound features and the severity of PCOS in obese and non obese patients, investigate the association between ultrasound characteristics and how PCOS effect both obese and non obese, assess the potential of using ultrasound features. By addressing these gaps, the research aimed to contribute to better understanding of PCOS.

Aim:

To compare the ultrasound features of polycystic ovaries between obese and non-obese patients.

Methodology:

A prospective observational design was conducted at Gilani Ultrasound Center in Lahore. A total of 100 participants were included using a non-probability purposive sampling technique. Data collection spanned a period of 9 months. The study included females of all ages, categorized into four groups: obese with PCOS, obese without PCOS, non-obese with PCOS, and non-obese without PCOS. Exclusion criteria involved females with treated PCOS, those undergoing infertility treatment, individuals with congenital anomalies, and those with ovarian abnormalities other than PCOS.

Results:

The study included 126 participants with a mean age of 28.7 ± 4.6 years, ranging from 20

to 36 years. Of these, 84 (66.7%) had polycystic ovaries, while 42 (33.3%) were healthy controls. The participants were almost evenly split between married (46.8%) and single (53.2%). The mean BMI was 27.6 ± 5.1 , with participants equally distributed among normal, overweight, and obese categories (33.3% each). Other notable characteristics included hirsutism (38.9%), acne (28.6%), diabetes (50.8%), hypertension (19.8%), amenorrhea (50%), and infertility (41.3%).

Within-group analysis showed that in the PCOS group, there was a significant association between PCOS and obesity ($p = 0.01$), while no significant association was found in the non-obese group ($p = 0.98$). The mean BMI for the normal weight group was 22.4 ± 0.01 , for the overweight group 28.10 ± 1.3 , and for the obese group 33.26 ± 2.25 . The mean ovarian volumes were similar for both left ($16.452 \pm 8.2930 \text{ cm}^3$) and right ($16.573 \pm 8.2358 \text{ cm}^3$) ovaries.

Between-group analysis revealed several significant associations with PCOS. There was a strong link between PCOS and string-like appearance of ovaries ($p < 0.001$), diabetes ($p = 0.040$), hypertension ($p = 0.040$), amenorrhea ($p < 0.001$), and infertility ($p = 0.02$). Hormonal analyses showed significant associations between PCOS and thyroid dysfunction ($p < 0.001$), progesterone levels ($p < 0.001$), LH levels ($p = 0.030$), testosterone levels ($p = 0.001$), and FSH levels ($p = 0.022$). However, no significant associations were found between PCOS and marital status, estrogen levels, or prolactin levels.

Table 1: Group Statistics BMI

	Normal BMI group	Overweight group	Obese group
Mean BMI	22.4 ± 0.01	28.10 ± 1.3	33.26 ± 2.25

The mean + SD BMI of normal group was 22.4 ± 0.01 , mean + SD BMI of Overweight

group was 28.10 ± 1.3 and mean + SD BMI of obese group was 33.26 ± 2.25 (Table 1).

Table 2: Statistics of Left ovarian volume and Right ovarian volume

	Left Ovary Volume	Right ovary volume
Mean	16.452	16.573
Std. Error of Mean	.7388	.7337
Std. Deviation	8.2930	8.2358
Variance	68.773	67.829
Minimum	5.1	4.7
Maximum	32.1	30.5

The mean \pm SD ovarian volume on left side was 16.45 ± 8.2 and on right side 16.5 ± 8.2 (Table 2).

Discussion:

Polycystic ovary syndrome (PCOS) is the most common endocrine and metabolic disorder in women with a prevalence of up to 17.8%, and is characterized by hyperandrogenism, irregular cycles and polycystic ovaries. Obesity and an aberrant metabolic profile are common in women with PCOS, and 50- 70% of them are insulin resistant. Most women with PCOS are able to compensate for their insulin resistance (IR), but a large proportion of them have altered beta-cell function causing glucose intolerance, which increases the risk of developing type 2 diabetes (T2D), independently of body mass index (BMI) and age. Further, women with PCOS have an increased risk of developing dyslipidemia and hypertension with an increased prevalence of metabolic syndrome. The etiology of PCOS is unclear, but it is thought to be multifactorial. There is a strong

association between hyperinsulinemia and hyperandrogenism (HA) in PCOS, but the mechanisms behind their relationship with PCOS are not fully understood¹⁹.

Sipahi et al. (2019) investigated ultrasound findings that could predict MetS in PCOS patients. They found that 15.6% of PCOS patients had MetS, with a higher mean ovarian volume (OV) in MetS patients (11.7 mL) compared to non-MetS patients (9.6 mL). The study determined an optimal OV cut-off of 9.2 mL for predicting MetS, with 80% sensitivity and 50.6% specificity. This suggests that PCOS patients with higher OV values may have an increased risk of developing MetS²⁰.

Memon et al. (2020) conducted a cross-sectional study on females aged 16-40 years, finding a PCOS prevalence of 48.5% using Rotterdam criteria. PCOS patients showed higher BMI, waist circumference, and systolic blood pressure compared to non-PCOS participants. The study highlighted that PCOS patients exhibit hormonal and metabolic abnormalities, as well as menstrual irregularities, regardless of their weight²¹.

Odera O (2015) studied the prevalence of PCOS among women with amenorrhea and oligomenorrhea at Kenyatta National Hospital. Using Rotterdam criteria, 37.4% of participants were diagnosed with PCOS. The mean age of PCOS patients was 25.9 years, with a mean BMI of 25.9. This study emphasized that PCOS should be a primary consideration when evaluating women with oligomenorrhea or amenorrhea²².

Aalei B and Naderi T (2014) investigated PCOS characteristics and their interrelationships in Kerman. They found oligomenorrhea and hirsutism to be the most frequent complaints among PCOS patients. The study revealed significant relationships between various hormonal levels and clinical features, such as LH/FSH > 2 and hirsutism, and hyperprolactinemia and galactorrhea. However, no significant relationships were found between hormonal status and ultrasound or clinical features²³.

Chen et al. (2008) investigated OV as a diagnostic criterion for Chinese adolescents with PCOS. They found that mean and maximum OV were significantly larger in PCOS patients compared to controls. The study determined optimal thresholds for mean OV (6.74 cm³) and maximum OV (7.82 cm³) for diagnosing PCOS in Chinese adolescents,

which were lower than the 10 cm³ threshold proposed by the Rotterdam consensus²⁴.

Chun et al. (2019) examined differences in ovarian size between the right and left ovaries in Korean women with PCOS. They found that the right ovary had significantly higher antral follicle count (26.75 vs 23.98) and larger volume (11.06 cm³ vs 9.12 cm³) compared to the left ovary²⁵.

Lee NS et al. (2021) explored the relationship between OV, anthropometry, and hormonal levels in PCOS patients. They found that mean OV was significantly larger in the PCOS group (7.65 cm³) compared to the non-PCOS group (6.08 cm³). OV positively correlated with serum anti-Müllerian hormone (AMH) and luteinizing hormone (LH) levels²⁶.

Han et al. (2017) studied OV and follicle number (FN) in Korean women with PCOS. They reported mean OVs of 7.9 cm³ (right) and 6.7 cm³ (left), which were smaller than those observed in other ethnic groups. Serum AMH and testosterone levels were found to be good markers for PCOS diagnosis in Korean women²⁷.

Yang et al. (2015) investigated the relationship between iron status, obesity, and ovarian reserve in women with PCOS. They found that obese women with PCOS had higher ferritin levels but lower AMH levels compared to non-obese women with PCOS. Elevated ferritin levels and obesity were negatively associated with ovarian volume and AMH levels, respectively²⁸.

The results from this study are largely in concordance with the findings from the previously mentioned studies, particularly in several key areas. The mean ovarian volumes reported (16.452 ± 8.2930 cm³ for left and 16.573 ± 8.2358 cm³ for right ovaries) are significantly higher than the thresholds proposed in earlier studies. Chen et al²⁴. (2008) suggested a threshold of 7.82 cm³ for maximum ovarian volume, while Lee NS et al²⁶. (2021) reported a mean ovarian volume of 7.65 cm³ in PCOS patients. This aligns with the consistent finding that PCOS patients tend to have larger ovarian volumes compared to healthy controls.

The significant association between PCOS and obesity (p = 0.01) in this study corroborates findings from Yang et al²⁸. (2015), who reported that obese women with

PCOS had different hormonal profiles compared to non-obese women with PCOS⁵. This reinforces the importance of considering BMI in PCOS diagnosis and management. The significant associations found between PCOS and various hormonal levels (LH, FSH, testosterone, progesterone) align with the hormonal abnormalities typically observed in PCOS patients, as mentioned in several of the cited studies.

The high prevalence of hirsutism (38.9%), acne (28.6%), amenorrhea (50%), and infertility (41.3%) in the PCOS group is consistent with the common symptoms of PCOS described in the NHS and WHO fact sheets. The strong associations between PCOS and diabetes ($p = 0.040$) and hypertension ($p = 0.040$) support the findings from previous studies that PCOS patients are at higher risk for metabolic syndrome and cardiovascular complications. The significant association between PCOS and the string-like appearance of ovaries ($p < 0.001$) aligns with the ultrasound criteria for polycystic ovaries mentioned in several studies.

Conclusion:

In conclusion, polycystic ovary syndrome (PCOS) is a complex endocrine disorder characterized by a diverse array of hormonal imbalances, metabolic disturbances, and distinctive ovarian morphology. The syndrome's heterogeneity, manifesting in various phenotypes and associated health risks, underscores the need for a comprehensive approach to diagnosis and management

References:

1. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The Prevalence And Features Of The Polycystic Ovary Syndrome In An Unselected Population. *J Clin Endocrinol Metab.* 2004;89:2745–2749.



2. Diamanti-Kandarakis E, Kouli CR, Bergiele AT, Et Al. A Survey Of The Polycystic Ovary Syndrome In The Greek Island Of Lesbos: Hormonal And Metabolic Profile. *J Clin Endocrinol Metab.* 1999;84: 4006–4011.
3. Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R. Prevalence Of The Polycystic Ovary Syndrome In Unselected Black And White Women Of The Southeastern United States: A Prospective Study. *J Clin Endocrinol Metab.* 1998;83:3078–3082.
4. Michelmore KF, Balen AH, Dunger DB, Vessey MP. Polycystic Ovaries And Associated Clinical And Biochemical Features In Young Women. *Clin Endocrinol (Oxf).* 1999;51:779–786.
5. Asuncion M, Calvo RM, San Millan JL, Sancho J, Avila S, Escobarmorreale HF. A Prospective Study Of The Prevalence Of The Polycystic Ovary Syndrome In Unselected Caucasian Women From Spain. *J Clin Endocrinol Metab.* 2000;85:2434–2438.
6. March WA, Moore VM, Willson KJ, Phillips DI, Norman RJ, Davies MJ. The Prevalence Of Polycystic Ovary Syndrome In A Community Sample Assessed Under Contrasting Diagnostic Criteria. *Hum Reprod.* 2010;25(2): 544–551.
7. Mehrabian F, Khani B, Kelishadi R, Ghanbari E. The Prevalence Of Polycystic Ovary Syndrome In Iranian Women Based On Different Diagnostic Criteria. *Endokrynol Pol.* 2011;62(3):238–242.
8. Tehrani FR, Simbar M, Tohidi M, Hoseinpanah F, Azizi F. The Prevalence Of Polycystic Ovary Syndrome In A Community Sample Of Iranian Population: Iranian PCOS Prevalence Study. *Reprod Biol Endocrinol.* 2011;9:39.
9. Chang RJ, Nakamura RM, Judd HL, Kaplan SA. Insulin Resistance In Nonobese Patients With Polycystic Ovarian Disease. *J Clin Endocrinol Metab* 1983;57:356-9.
10. Dunaif A, Segal KR, Futterweit W, Drobrjansky A. Profound Peripheral Insulin Resistance, Independent Of Obesity, In Polycystic Ovary Syndrome. *Diabetes* 1989;38:1165-74.

11. Franks S, Gharani N, Waterworth D, Et Al. The Genetic Basis Of Polycystic Ovary Syndrome. *Hum Reprod.* 1997;12:2641–2648.
12. Legro RS, Driscoll D, Straus III JF, Fox J, Dunaif A. Evidence For A Genetic Basis For Hyperandrogenemia In Polycystic Ovary Syndrome. *Proc Natl Acad Sci U S A.* 1998;95:14956–14960.
13. Amato P, Simpson JL. The Genetics Of Polycystic Ovary Syndrome. *Best Pract Res Clin ObstetGynaecol.* 2004;18(5):707–718.
14. Crosignani PG, Nicolosi AE. Polycystic Ovarian Disease: Heritability And Heterogeneity. *Hum Reprod Update.* 2001;7(1):3–7.
15. Azziz R, Sanchez L, Knochenhauer ES, Et Al. Androgen Excess In Women: Experience With Over 1000 Consecutive Patients. *J Clin Endocrinol Metab.* 2004;89(2):453–462.
16. Fauser B, Tarlatzis B, Rebar R, Et Al. Consensus On Women’s Health Aspects Of Polycystic Ovary Syndrome (PCOS): The Amsterdam ESHRE/ ASRM-Sponsored 3rd PCOS Consensus Workshop Group. *FertilSteril.* 2012;97(1):28–38. E25.
17. Ferriman D, Gallwey J. Clinical Assessment Of Body Hair Growth In Women. *J Clin Endocrinol Metab.* 1961;21:1440–1447.
18. Wijeyaratne CN, Balen AH, Barth JH, Belchetz PE. Clinical Manifestations And Insulin Resistance (IR) In Polycystic Ovary Syndrome (PCOS) Among South Asians And Caucasians: Is There A Difference? *Clin Endocrinol (Oxf).* 2002;57:343–350.
19. Asuncion M, Calvo RM, San Millan JL, Sancho J, Avila S, Escobarmorreale HF. A Prospective Study Of The Prevalence Of The Polycystic Ovary Syndrome In Unselected Caucasian Women From Spain. *J Clin Endocrinol Metab.* 2019;85:2434–2438.
20. Sipahi M, Tokgöz VY, Keskin Ö, Atasever M, Menteşe A, Demir S. Is ovarian volume a good predictor to determine metabolic syndrome development in polycystic ovary patients. *Journal of Obstetrics and Gynaecology.* 2019 Apr 3;39(3):372-6.
21. Memon TF, Meghji KA, Rajar AB, Khowaja S, Azam A, Khatoon S. Clinical, hormonal and metabolic factors associated with polycystic ovary syndrome among Pakistani women. *Rawal Medical Journal.* 2020 Oct;45(4):817-.

22. Odera FO. Prevalence of polycystic ovary syndrome among women presenting with amenorrhea and oligomenorrhea at the kenyatta national hospital.2015.6 (3). 187-192
23. AALEI B, Naderi T. Polycystic ovarian syndrome: clinical, ultrasound and laboratory characteristics, kerman, 2014. 4(1) 1381.1389
24. Chen Y, Yang D, Li L, Chen X. The role of ovarian volume as a diagnostic criterion for Chinese adolescents with polycystic ovary syndrome. Journal of pediatric and adolescent gynecology. 2008 Dec 1;21(6):347-50.
25. Chun S. Inter-ovarian differences in ultrasound markers of ovarian size in women with polycystic ovary syndrome. Clinical and Experimental Reproductive Medicine. 2019 Dec;46(4):197.
26. Le NS, Le MT, Nguyen ND, Tran NQ, Nguyen QH, Cao TN. A Cross-Sectional Study on Potential Ovarian Volume and Related Factors in Women with Polycystic Ovary Syndrome from Infertile Couples. International Journal of Women's Health. 2021;13:793.
27. Han YS, Lee AR, Song HK, Choi JI, Kim JH, Kim MR, Kim MJ. Ovarian volume in Korean women with polycystic ovary syndrome and its related factors. Journal of Menopausal Medicine. 2017 Apr 1;23(1):25-31.
28. Yang JH, Chou CH, Yang WS, Ho HN, Yang YS, Chen MJ. Iron stores and obesity are negatively associated with ovarian volume and anti-Müllerian hormone levels in women with polycystic ovary syndrome. Taiwanese journal of obstetrics and gynecology. 2015 Dec 1;54(6):686-92.

CASE 1:

Ultrasound images of 25 year-old obese unmarried females with polycystic ovaries.



CASE 2: Ultrasound images of 27-year-old unmarried females with polycystic ovaries.



